TNF Pharmaceuticals announced that it has secured a strategic equity investment, priced at a 20% premium to a 30-trading days volume weighted average price, from Prevail Partner, a U.S. investment fund focused on life sciences companies. The company has engaged global full-service clinical research organization Prevail InfoWorks, Inc., an affiliate of Prevail Partners, to provide clinical services for the next Phase 2 clinical study using our proprietary drug in sarcopenia/frailty. Prevail Partners has agreed to purchase 283,019 shares of TNFA common stock at a price of $2.12 per share, representing a 20% premium to the company’s 30-trading days VWAP as of the closing date of October 1, 2024.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNFA: